- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed and/or refractory follicular lymphoma (FL)
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 1.4MB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 2.8MB)
Tafasitamab – November 2025
Tafasitamab: Powder for I.V. infusion 200 mg; Minjuvi® - November 2025
Last updated
5 November 2025